Literature DB >> 31568934

Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Raminta Daniulaityte1, Ramzi W Nahhas2, Sydney Silverstein3, Silvia Martins4, Angela Zaragoza3, Avery Moeller3, Robert G Carlson3.   

Abstract

AIM: Non-prescribed buprenorphine (NPB) use increased in the US. This study aims to characterize heterogeneity in patterns of NPB and other opioid use among individuals with current opioid use disorder.
METHODS: The study recruited 356 participants in Dayton (Montgomery County), Ohio, area in 2017-2018 using targeted and Respondent Driven Sampling. Participants met the following criteria: 1) 18 years or older, 2) current moderate/severe opioid use disorder (DSM-5), 3) past 6-month NPB use. Latent class analysis (LCA) was conducted to identify subgroups based on past 6-month (days of NPB and heroin/fentanyl use; use of NPB to get high; use of non-prescribed and prescribed pharmaceutical opioids; participation in formal treatment) and lifetime (years since first NPB and other illicit opioid use) characteristics. Selected auxiliary variables were compared across classes using Asparouhov and Muthén's 3-step approach.
RESULTS: 49.7% were female, and 88.8% were non-Hispanic whites. 89% used NPB to self-treat withdrawal. LCA resulted in three classes: "Heavy Heroin/Fentanyl Use" (61%), "More Formal Treatment Use" (29%) and "Intense NPB Use" (10%). After adjusting for multiple testing, the following past 6-month variables differed significantly between classes: injection as a primary route of heroin/fentanyl administration (p < 0.001), cocaine use (p = 0.044), unintentional drug overdose (p = 0.023), and homelessness (p = 0.044), with the "Intense NPB Use" class having the lowest prevalences.
CONCLUSION: Predominance of self-treatment goals and the association between more intense NPB use and lower risks of adverse consequences suggest potential harm minimization benefits of NPB use. More research is needed to understand consequences of NPB use over time.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Buprenorphine diversion; Heroin; Illicit opioids; Non-pharmaceutical fentanyl; Overdose; Self-treatment

Year:  2019        PMID: 31568934      PMCID: PMC6886684          DOI: 10.1016/j.drugalcdep.2019.107574

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  51 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Maintenance drugs to treat opioid dependence.

Authors:  Michael Farrell; Alex Wodak; Linda Gowing
Journal:  BMJ       Date:  2012-05-15

3.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

Review 4.  Self-report among injecting drug users: a review.

Authors:  S Darke
Journal:  Drug Alcohol Depend       Date:  1998-08-01       Impact factor: 4.492

Review 5.  How fast and how often: The pharmacokinetics of drug use are decisive in addiction.

Authors:  Florence Allain; Ellie-Anna Minogianis; David C S Roberts; Anne-Noël Samaha
Journal:  Neurosci Biobehav Rev       Date:  2015-06-24       Impact factor: 8.989

6.  Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Authors:  Michelle R Lofwall; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2012-06-15       Impact factor: 4.492

7.  Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

Authors:  Dennis M Donovan; George E Bigelow; Gregory S Brigham; Kathleen M Carroll; Allan J Cohen; John G Gardin; John A Hamilton; Marilyn A Huestis; John R Hughes; Robert Lindblad; G Alan Marlatt; Kenzie L Preston; Jeffrey A Selzer; Eugene C Somoza; Paul G Wakim; Elizabeth A Wells
Journal:  Addiction       Date:  2011-07-22       Impact factor: 6.526

8.  Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.

Authors:  Bennett Allen; Alex Harocopos
Journal:  J Subst Abuse Treat       Date:  2016-08-12

9.  Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015-2017.

Authors:  Raminta Daniulaityte; Matthew P Juhascik; Kraig E Strayer; Ioana E Sizemore; Mussa Zatreh; Ramzi W Nahhas; Kent E Harshbarger; Heather M Antonides; Silvia S Martins; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-03-18       Impact factor: 4.852

10.  Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.

Authors:  Elenore Patterson Bhatraju; Ellie Grossman; Babak Tofighi; Jennifer McNeely; Danae DiRocco; Mara Flannery; Ann Garment; Keith Goldfeld; Marc N Gourevitch; Joshua D Lee
Journal:  Addict Sci Clin Pract       Date:  2017-02-28
View more
  8 in total

1.  Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats.

Authors:  E Andrew Townsend; Paul T Bremer; Kaycee E Faunce; S Stevens Negus; Alaina M Jaster; Hannah L Robinson; Kim D Janda; Matthew L Banks
Journal:  ACS Chem Neurosci       Date:  2020-04-22       Impact factor: 4.418

2.  Methamphetamine Use and Its Correlates among Individuals with Opioid Use Disorder in a Midwestern U.S. City.

Authors:  Raminta Daniulaityte; Sydney M Silverstein; Timothy N Crawford; Silvia S Martins; William Zule; Angela J Zaragoza; Robert G Carlson
Journal:  Subst Use Misuse       Date:  2020-05-22       Impact factor: 2.164

3.  Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs.

Authors:  Ricky N Bluthenthal; Kelsey Simpson; Rachel Carmen Ceasar; Johnathan Zhao; Lynn Wenger; Alex H Kral
Journal:  Drug Alcohol Depend       Date:  2020-03-18       Impact factor: 4.492

4.  On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.

Authors:  Sydney M Silverstein; Raminta Daniulaityte; Shannon C Miller; Silvia S Martins; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2020-03-16       Impact factor: 4.492

5.  Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?

Authors:  Robert G Carlson; Raminta Daniulaityte; Sydney M Silverstein; Ramzi W Nahhas; Silvia S Martins
Journal:  Int J Drug Policy       Date:  2020-04-17

6.  Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.

Authors:  Beth Han; Christopher M Jones; Emily B Einstein; Wilson M Compton
Journal:  JAMA Netw Open       Date:  2021-10-01

7.  Problematic Opioid Use: A Scoping Literature Review of Profiles.

Authors:  Léonie Archambault; Karine Bertrand; Michel Perreault
Journal:  Subst Abuse       Date:  2022-07-28

Review 8.  Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

Authors:  E Andrew Townsend; Matthew L Banks
Journal:  CNS Drugs       Date:  2020-05       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.